AstraZeneca's First-in-Class Subcutaneous Biologic Saphnelo (Anifrolumab) Meets Primary Endpoint in Phase III TULIP-SC Trial for Systemic Lupus Erythematosus

On September 17, AstraZeneca announced that itsSubcutaneous Injection Pioneering Biologic Saphnelo （Anifrolumab，Anirud monoclonal antibody subcutaneous injection）TargetingSystemic Lupus Erythematosus (SLE)Pre-specified interim analysis of the Phase III TULIP-SC trial in patientsAchieve the primary endpoint。

Screenshot source: AstraZeneca official website

TULIP-SC is aPhase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study designed to evaluate in patients receiving standard of care (SOC) In patients with moderate to severe active autoantibody-positive SLE, subcutaneous injectionSaphnelo Efficacy and safety compared to placebo.

Results show that, compared with placebo, Saphnelo subcutaneous injection(SC) TherapySignificantly reduced disease activity, and is clinically significant. The safety observed in the interim analysis is consistent with Saphnelo intravenous (IV)The known clinical characteristics of infusion are consistent. Specific research data will be presented from October 24 to 29, 2025, at the American College of Rheumatology. (ACR) Convergence 2025 Annual Meeting Announcement.

Saphnelo is a first-in-class fully human monoclonal antibody that binds to type I interferon.(IFN)Receptor subunit 1 binding, thereby blocking the activity of type I interferons. Type I interferons, such as IFN-α, IFN-β, and IFN-κ, are cytokines involved in regulating inflammation pathways associated with SLE.

Source: DXYInsight Database